Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH)’s stock price was down 3.5% on Monday . The company traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares were traded during mid-day trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Stock Performance
The stock has a 50-day moving average of C$16.76. The stock has a market cap of C$2.15 billion and a P/E ratio of -11.32. The company has a current ratio of 11.93, a quick ratio of 11.02 and a debt-to-equity ratio of 2.69.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- United Airlines Soars on Earnings Beat
- Which Wall Street Analysts are the Most Accurate?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
